Centrient Pharmaceuticals

Centrient Pharmaceuticals, a Netherlands-headquartered company in the Pharmaceutical Preparation Manufacturing industry, reported its most recent carbon emissions for 2025 at approximately 601,812,000 kg CO2e. This total includes:

• Scope 1 emissions: Approximately 101,489,000 kg CO2e, primarily from stationary combustion (96,758,000 kg CO2e) and fugitive emissions (4,672,000 kg CO2e).
• Scope 2 (market-based) emissions: Approximately 148,005,000 kg CO2e, with purchased electricity accounting for about 143,415,000 kg CO2e.
• Scope 3 emissions: Approximately 352,318,000 kg CO2e, largely driven by purchased goods and services (244,419,000 kg CO2e), fuel and energy-related activities (47,690,000 kg CO2e), and processing of sold products (27,638,000 kg CO2e).

Looking back, Centrient Pharmaceuticals' total emissions were approximately 697,019,000 kg CO2e in 2024 and 732,956,000 kg CO2e in 2023. In 2022, total emissions were about 641,257,000 kg CO2e, comprising approximately 136,734,000 kg CO2e for Scope 1, 145,740,000 kg CO2e for Scope 2 (market-based), and 358,783,000 kg CO2e for Scope 3.

Climate Commitments and Targets: Centrient Pharmaceuticals has set ambitious climate targets, which are validated by the Science Based Targets initiative (SBTi) and cascaded through Centrient Holding B.V.

• Near-term SBTi Target: The company commits to reduce absolute Scope 1 and 2 GHG emissions by 46.2% by 2031, using 2022 as a base year. This target is considered consistent with keeping global warming to 1.5°C.
• Scope 3 Target: Centrient Pharmaceuticals also commits to reduce absolute Scope 3 GHG emissions from purchased goods and services and fuel and energy-related activities by 27.5% within the same 2022-2031 timeframe.
• Other Targets: The company aims for a 35% reduction in carbon emission intensity by 2025 and a 50% reduction by 2030, using 2021 as a base year. They also report having achieved a 7.5% intensity reduction in tCO2e/tonne produced between 2021 and 2025.